CN104054828A - Infant formula milk powder resisting protein allergy and preparation method thereof - Google Patents
Infant formula milk powder resisting protein allergy and preparation method thereof Download PDFInfo
- Publication number
- CN104054828A CN104054828A CN201410282958.4A CN201410282958A CN104054828A CN 104054828 A CN104054828 A CN 104054828A CN 201410282958 A CN201410282958 A CN 201410282958A CN 104054828 A CN104054828 A CN 104054828A
- Authority
- CN
- China
- Prior art keywords
- parts
- hydrolysis
- formula
- oil
- infant formula
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
- 235000013350 formula milk Nutrition 0.000 title claims abstract description 78
- 239000000843 powder Substances 0.000 title claims abstract description 42
- 238000002360 preparation method Methods 0.000 title claims abstract description 21
- 206010016946 Food allergy Diseases 0.000 title abstract description 6
- 235000013336 milk Nutrition 0.000 title abstract description 6
- 239000008267 milk Substances 0.000 title abstract description 6
- 210000004080 milk Anatomy 0.000 title abstract description 6
- 230000007062 hydrolysis Effects 0.000 claims abstract description 74
- 238000006460 hydrolysis reaction Methods 0.000 claims abstract description 74
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Chemical compound O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 claims abstract description 32
- 239000000413 hydrolysate Substances 0.000 claims abstract description 24
- 102000007544 Whey Proteins Human genes 0.000 claims abstract description 17
- 108010046377 Whey Proteins Proteins 0.000 claims abstract description 17
- 235000021119 whey protein Nutrition 0.000 claims abstract description 17
- 102000004400 Aminopeptidases Human genes 0.000 claims abstract description 14
- 108090000915 Aminopeptidases Proteins 0.000 claims abstract description 14
- 102000004190 Enzymes Human genes 0.000 claims abstract description 10
- 108090000790 Enzymes Proteins 0.000 claims abstract description 10
- 108010009736 Protein Hydrolysates Proteins 0.000 claims abstract description 10
- 239000012153 distilled water Substances 0.000 claims abstract description 10
- 238000000034 method Methods 0.000 claims abstract description 10
- 230000001105 regulatory effect Effects 0.000 claims abstract description 8
- XOAAWQZATWQOTB-UHFFFAOYSA-N taurine Chemical compound NCCS(O)(=O)=O XOAAWQZATWQOTB-UHFFFAOYSA-N 0.000 claims description 40
- 102000004407 Lactalbumin Human genes 0.000 claims description 37
- 108090000942 Lactalbumin Proteins 0.000 claims description 37
- 206010020751 Hypersensitivity Diseases 0.000 claims description 33
- -1 diglycerol fatty acid Chemical class 0.000 claims description 33
- 208000026935 allergic disease Diseases 0.000 claims description 32
- 230000007815 allergy Effects 0.000 claims description 32
- 239000000203 mixture Substances 0.000 claims description 27
- 239000003995 emulsifying agent Substances 0.000 claims description 26
- 229910052500 inorganic mineral Inorganic materials 0.000 claims description 26
- 235000020978 long-chain polyunsaturated fatty acids Nutrition 0.000 claims description 26
- 239000011707 mineral Substances 0.000 claims description 26
- 239000002773 nucleotide Substances 0.000 claims description 26
- 125000003729 nucleotide group Chemical group 0.000 claims description 26
- 235000015112 vegetable and seed oil Nutrition 0.000 claims description 26
- 239000008158 vegetable oil Substances 0.000 claims description 26
- WQZGKKKJIJFFOK-GASJEMHNSA-N Glucose Natural products OC[C@H]1OC(O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-GASJEMHNSA-N 0.000 claims description 22
- YZXBAPSDXZZRGB-DOFZRALJSA-N arachidonic acid Chemical compound CCCCC\C=C/C\C=C/C\C=C/C\C=C/CCCC(O)=O YZXBAPSDXZZRGB-DOFZRALJSA-N 0.000 claims description 22
- 239000008103 glucose Substances 0.000 claims description 22
- 239000007787 solid Substances 0.000 claims description 22
- 239000006188 syrup Substances 0.000 claims description 22
- 235000020357 syrup Nutrition 0.000 claims description 22
- UFTFJSFQGQCHQW-UHFFFAOYSA-N triformin Chemical compound O=COCC(OC=O)COC=O UFTFJSFQGQCHQW-UHFFFAOYSA-N 0.000 claims description 22
- 239000001763 2-hydroxyethyl(trimethyl)azanium Substances 0.000 claims description 20
- 235000019743 Choline chloride Nutrition 0.000 claims description 20
- 229960003178 choline chloride Drugs 0.000 claims description 20
- SGMZJAMFUVOLNK-UHFFFAOYSA-M choline chloride Chemical compound [Cl-].C[N+](C)(C)CCO SGMZJAMFUVOLNK-UHFFFAOYSA-M 0.000 claims description 20
- 229960003080 taurine Drugs 0.000 claims description 20
- 239000004615 ingredient Substances 0.000 claims description 18
- 239000000463 material Substances 0.000 claims description 18
- 238000002156 mixing Methods 0.000 claims description 18
- 239000003921 oil Substances 0.000 claims description 16
- 235000019198 oils Nutrition 0.000 claims description 16
- YBJHBAHKTGYVGT-ZKWXMUAHSA-N (+)-Biotin Chemical compound N1C(=O)N[C@@H]2[C@H](CCCCC(=O)O)SC[C@@H]21 YBJHBAHKTGYVGT-ZKWXMUAHSA-N 0.000 claims description 12
- 241000196324 Embryophyta Species 0.000 claims description 12
- XEEYBQQBJWHFJM-UHFFFAOYSA-N Iron Chemical compound [Fe] XEEYBQQBJWHFJM-UHFFFAOYSA-N 0.000 claims description 12
- PVNIIMVLHYAWGP-UHFFFAOYSA-N Niacin Chemical compound OC(=O)C1=CC=CN=C1 PVNIIMVLHYAWGP-UHFFFAOYSA-N 0.000 claims description 12
- MNCUCCJMXIWMJJ-OWOJBTEDSA-N [(e)-2-thiocyanatoethenyl] thiocyanate Chemical group N#CS\C=C\SC#N MNCUCCJMXIWMJJ-OWOJBTEDSA-N 0.000 claims description 12
- OVBPIULPVIDEAO-LBPRGKRZSA-N folic acid Chemical compound C=1N=C2NC(N)=NC(=O)C2=NC=1CNC1=CC=C(C(=O)N[C@@H](CCC(O)=O)C(O)=O)C=C1 OVBPIULPVIDEAO-LBPRGKRZSA-N 0.000 claims description 12
- 239000008213 purified water Substances 0.000 claims description 12
- 238000003756 stirring Methods 0.000 claims description 12
- 235000021342 arachidonic acid Nutrition 0.000 claims description 11
- 229940114079 arachidonic acid Drugs 0.000 claims description 11
- 238000001556 precipitation Methods 0.000 claims description 7
- OYPRJOBELJOOCE-UHFFFAOYSA-N Calcium Chemical compound [Ca] OYPRJOBELJOOCE-UHFFFAOYSA-N 0.000 claims description 6
- RYGMFSIKBFXOCR-UHFFFAOYSA-N Copper Chemical compound [Cu] RYGMFSIKBFXOCR-UHFFFAOYSA-N 0.000 claims description 6
- OVBPIULPVIDEAO-UHFFFAOYSA-N N-Pteroyl-L-glutaminsaeure Natural products C=1N=C2NC(N)=NC(=O)C2=NC=1CNC1=CC=C(C(=O)NC(CCC(O)=O)C(O)=O)C=C1 OVBPIULPVIDEAO-UHFFFAOYSA-N 0.000 claims description 6
- OAICVXFJPJFONN-UHFFFAOYSA-N Phosphorus Chemical compound [P] OAICVXFJPJFONN-UHFFFAOYSA-N 0.000 claims description 6
- ZLMJMSJWJFRBEC-UHFFFAOYSA-N Potassium Chemical compound [K] ZLMJMSJWJFRBEC-UHFFFAOYSA-N 0.000 claims description 6
- BUGBHKTXTAQXES-UHFFFAOYSA-N Selenium Chemical compound [Se] BUGBHKTXTAQXES-UHFFFAOYSA-N 0.000 claims description 6
- HCHKCACWOHOZIP-UHFFFAOYSA-N Zinc Chemical compound [Zn] HCHKCACWOHOZIP-UHFFFAOYSA-N 0.000 claims description 6
- 229960002685 biotin Drugs 0.000 claims description 6
- 235000020958 biotin Nutrition 0.000 claims description 6
- 239000011616 biotin Substances 0.000 claims description 6
- 239000011575 calcium Substances 0.000 claims description 6
- 229910052791 calcium Inorganic materials 0.000 claims description 6
- 229960001231 choline Drugs 0.000 claims description 6
- OEYIOHPDSNJKLS-UHFFFAOYSA-N choline Chemical compound C[N+](C)(C)CCO OEYIOHPDSNJKLS-UHFFFAOYSA-N 0.000 claims description 6
- 229910052802 copper Inorganic materials 0.000 claims description 6
- 239000010949 copper Substances 0.000 claims description 6
- 238000001035 drying Methods 0.000 claims description 6
- 238000001704 evaporation Methods 0.000 claims description 6
- 230000008020 evaporation Effects 0.000 claims description 6
- 229960000304 folic acid Drugs 0.000 claims description 6
- 235000019152 folic acid Nutrition 0.000 claims description 6
- 239000011724 folic acid Substances 0.000 claims description 6
- 239000008236 heating water Substances 0.000 claims description 6
- 229910052742 iron Inorganic materials 0.000 claims description 6
- 229960003512 nicotinic acid Drugs 0.000 claims description 6
- 235000001968 nicotinic acid Nutrition 0.000 claims description 6
- 239000011664 nicotinic acid Substances 0.000 claims description 6
- 238000009928 pasteurization Methods 0.000 claims description 6
- 239000011574 phosphorus Substances 0.000 claims description 6
- 229910052698 phosphorus Inorganic materials 0.000 claims description 6
- 239000011772 phylloquinone Substances 0.000 claims description 6
- 239000011591 potassium Substances 0.000 claims description 6
- 229910052700 potassium Inorganic materials 0.000 claims description 6
- 239000002994 raw material Substances 0.000 claims description 6
- 239000011669 selenium Substances 0.000 claims description 6
- 229910052711 selenium Inorganic materials 0.000 claims description 6
- 238000005507 spraying Methods 0.000 claims description 6
- 230000001954 sterilising effect Effects 0.000 claims description 6
- 238000004659 sterilization and disinfection Methods 0.000 claims description 6
- 238000010792 warming Methods 0.000 claims description 6
- 239000011701 zinc Substances 0.000 claims description 6
- 229910052725 zinc Inorganic materials 0.000 claims description 6
- UHDGCWIWMRVCDJ-UHFFFAOYSA-N 1-beta-D-Xylofuranosyl-NH-Cytosine Natural products O=C1N=C(N)C=CN1C1C(O)C(O)C(CO)O1 UHDGCWIWMRVCDJ-UHFFFAOYSA-N 0.000 claims description 5
- JLPULHDHAOZNQI-ZTIMHPMXSA-N 1-hexadecanoyl-2-(9Z,12Z-octadecadienoyl)-sn-glycero-3-phosphocholine Chemical group CCCCCCCCCCCCCCCC(=O)OC[C@H](COP([O-])(=O)OCC[N+](C)(C)C)OC(=O)CCCCCCC\C=C/C\C=C/CCCCC JLPULHDHAOZNQI-ZTIMHPMXSA-N 0.000 claims description 5
- ZAMOUSCENKQFHK-UHFFFAOYSA-N Chlorine atom Chemical compound [Cl] ZAMOUSCENKQFHK-UHFFFAOYSA-N 0.000 claims description 5
- UHDGCWIWMRVCDJ-PSQAKQOGSA-N Cytidine Natural products O=C1N=C(N)C=CN1[C@@H]1[C@@H](O)[C@@H](O)[C@H](CO)O1 UHDGCWIWMRVCDJ-PSQAKQOGSA-N 0.000 claims description 5
- DGAQECJNVWCQMB-PUAWFVPOSA-M Ilexoside XXIX Chemical compound C[C@@H]1CC[C@@]2(CC[C@@]3(C(=CC[C@H]4[C@]3(CC[C@@H]5[C@@]4(CC[C@@H](C5(C)C)OS(=O)(=O)[O-])C)C)[C@@H]2[C@]1(C)O)C)C(=O)O[C@H]6[C@@H]([C@H]([C@@H]([C@H](O6)CO)O)O)O.[Na+] DGAQECJNVWCQMB-PUAWFVPOSA-M 0.000 claims description 5
- 235000019482 Palm oil Nutrition 0.000 claims description 5
- 239000000460 chlorine Substances 0.000 claims description 5
- 229910052801 chlorine Inorganic materials 0.000 claims description 5
- UHDGCWIWMRVCDJ-ZAKLUEHWSA-N cytidine Chemical compound O=C1N=C(N)C=CN1[C@H]1[C@H](O)[C@@H](O)[C@H](CO)O1 UHDGCWIWMRVCDJ-ZAKLUEHWSA-N 0.000 claims description 5
- PNDPGZBMCMUPRI-UHFFFAOYSA-N iodine Chemical compound II PNDPGZBMCMUPRI-UHFFFAOYSA-N 0.000 claims description 5
- WPBNNNQJVZRUHP-UHFFFAOYSA-L manganese(2+);methyl n-[[2-(methoxycarbonylcarbamothioylamino)phenyl]carbamothioyl]carbamate;n-[2-(sulfidocarbothioylamino)ethyl]carbamodithioate Chemical compound [Mn+2].[S-]C(=S)NCCNC([S-])=S.COC(=O)NC(=S)NC1=CC=CC=C1NC(=S)NC(=O)OC WPBNNNQJVZRUHP-UHFFFAOYSA-L 0.000 claims description 5
- 150000004712 monophosphates Chemical class 0.000 claims description 5
- 239000002540 palm oil Substances 0.000 claims description 5
- 229910052708 sodium Inorganic materials 0.000 claims description 5
- 239000011734 sodium Substances 0.000 claims description 5
- 229940083466 soybean lecithin Drugs 0.000 claims description 5
- 235000012424 soybean oil Nutrition 0.000 claims description 5
- 239000003549 soybean oil Substances 0.000 claims description 5
- GVJHHUAWPYXKBD-UHFFFAOYSA-N (±)-α-Tocopherol Chemical compound OC1=C(C)C(C)=C2OC(CCCC(C)CCCC(C)CCCC(C)C)(C)CCC2=C1C GVJHHUAWPYXKBD-UHFFFAOYSA-N 0.000 claims description 4
- KURVIXMFFSNONZ-WFIJOQBCSA-L disodium;[(2r,3s,4r,5r)-5-(2,4-dioxopyrimidin-1-yl)-3,4-dihydroxyoxolan-2-yl]methyl phosphate Chemical compound [Na+].[Na+].O[C@@H]1[C@H](O)[C@@H](COP([O-])([O-])=O)O[C@H]1N1C(=O)NC(=O)C=C1 KURVIXMFFSNONZ-WFIJOQBCSA-L 0.000 claims description 4
- 229940061671 uridine 5-mo-phos disod Drugs 0.000 claims description 4
- AEOBEOJCBAYXBA-UHFFFAOYSA-N A2P5P Natural products C1=NC=2C(N)=NC=NC=2N1C1OC(COP(O)(O)=O)C(O)C1OP(O)(O)=O AEOBEOJCBAYXBA-UHFFFAOYSA-N 0.000 claims description 3
- 235000019486 Sunflower oil Nutrition 0.000 claims description 3
- 235000005687 corn oil Nutrition 0.000 claims description 3
- 239000002285 corn oil Substances 0.000 claims description 3
- 235000014113 dietary fatty acids Nutrition 0.000 claims description 3
- 229930195729 fatty acid Natural products 0.000 claims description 3
- 239000000194 fatty acid Substances 0.000 claims description 3
- 239000002600 sunflower oil Substances 0.000 claims description 3
- FPIPGXGPPPQFEQ-UHFFFAOYSA-N 13-cis retinol Natural products OCC=C(C)C=CC=C(C)C=CC1=C(C)CCCC1(C)C FPIPGXGPPPQFEQ-UHFFFAOYSA-N 0.000 claims description 2
- VYZAMTAEIAYCRO-UHFFFAOYSA-N Chromium Chemical compound [Cr] VYZAMTAEIAYCRO-UHFFFAOYSA-N 0.000 claims description 2
- 235000005979 Citrus limon Nutrition 0.000 claims description 2
- 244000131522 Citrus pyriformis Species 0.000 claims description 2
- ZOKXTWBITQBERF-UHFFFAOYSA-N Molybdenum Chemical compound [Mo] ZOKXTWBITQBERF-UHFFFAOYSA-N 0.000 claims description 2
- 235000019484 Rapeseed oil Nutrition 0.000 claims description 2
- FPIPGXGPPPQFEQ-BOOMUCAASA-N Vitamin A Natural products OC/C=C(/C)\C=C\C=C(\C)/C=C/C1=C(C)CCCC1(C)C FPIPGXGPPPQFEQ-BOOMUCAASA-N 0.000 claims description 2
- 229930003316 Vitamin D Natural products 0.000 claims description 2
- QYSXJUFSXHHAJI-XFEUOLMDSA-N Vitamin D3 Natural products C1(/[C@@H]2CC[C@@H]([C@]2(CCC1)C)[C@H](C)CCCC(C)C)=C/C=C1\C[C@@H](O)CCC1=C QYSXJUFSXHHAJI-XFEUOLMDSA-N 0.000 claims description 2
- 229930003427 Vitamin E Natural products 0.000 claims description 2
- 239000002253 acid Substances 0.000 claims description 2
- FPIPGXGPPPQFEQ-OVSJKPMPSA-N all-trans-retinol Chemical compound OC\C=C(/C)\C=C\C=C(/C)\C=C\C1=C(C)CCCC1(C)C FPIPGXGPPPQFEQ-OVSJKPMPSA-N 0.000 claims description 2
- 229910052804 chromium Inorganic materials 0.000 claims description 2
- 239000011651 chromium Substances 0.000 claims description 2
- 150000002148 esters Chemical class 0.000 claims description 2
- WIGCFUFOHFEKBI-UHFFFAOYSA-N gamma-tocopherol Natural products CC(C)CCCC(C)CCCC(C)CCCC1CCC2C(C)C(O)C(C)C(C)C2O1 WIGCFUFOHFEKBI-UHFFFAOYSA-N 0.000 claims description 2
- 229940057917 medium chain triglycerides Drugs 0.000 claims description 2
- 229910052750 molybdenum Inorganic materials 0.000 claims description 2
- 239000011733 molybdenum Substances 0.000 claims description 2
- MBWXNTAXLNYFJB-LKUDQCMESA-N phylloquinone Chemical compound C1=CC=C2C(=O)C(C/C=C(C)/CCCC(C)CCCC(C)CCCC(C)C)=C(C)C(=O)C2=C1 MBWXNTAXLNYFJB-LKUDQCMESA-N 0.000 claims description 2
- 235000019155 vitamin A Nutrition 0.000 claims description 2
- 239000011719 vitamin A Substances 0.000 claims description 2
- 235000019166 vitamin D Nutrition 0.000 claims description 2
- 239000011710 vitamin D Substances 0.000 claims description 2
- 150000003710 vitamin D derivatives Chemical class 0.000 claims description 2
- 235000019165 vitamin E Nutrition 0.000 claims description 2
- 229940046009 vitamin E Drugs 0.000 claims description 2
- 239000011709 vitamin E Substances 0.000 claims description 2
- 229940045997 vitamin a Drugs 0.000 claims description 2
- 229940046008 vitamin d Drugs 0.000 claims description 2
- 235000019658 bitter taste Nutrition 0.000 abstract description 16
- 230000003301 hydrolyzing effect Effects 0.000 abstract description 7
- 230000000694 effects Effects 0.000 abstract description 6
- 238000010521 absorption reaction Methods 0.000 abstract description 5
- 108090000765 processed proteins & peptides Proteins 0.000 abstract description 5
- 102000004142 Trypsin Human genes 0.000 abstract description 2
- 108090000631 Trypsin Proteins 0.000 abstract description 2
- 230000029087 digestion Effects 0.000 abstract description 2
- 238000010438 heat treatment Methods 0.000 abstract description 2
- 235000019640 taste Nutrition 0.000 abstract description 2
- 239000012588 trypsin Substances 0.000 abstract description 2
- 239000003531 protein hydrolysate Substances 0.000 abstract 3
- 230000002009 allergenic effect Effects 0.000 abstract 1
- 230000002779 inactivation Effects 0.000 abstract 1
- 239000002244 precipitate Substances 0.000 abstract 1
- 102000014171 Milk Proteins Human genes 0.000 description 13
- 108010011756 Milk Proteins Proteins 0.000 description 13
- 235000021239 milk protein Nutrition 0.000 description 12
- 229940088594 vitamin Drugs 0.000 description 11
- 229930003231 vitamin Natural products 0.000 description 11
- 235000013343 vitamin Nutrition 0.000 description 11
- 239000011782 vitamin Substances 0.000 description 11
- 150000003722 vitamin derivatives Chemical class 0.000 description 11
- 235000018102 proteins Nutrition 0.000 description 10
- 102000004169 proteins and genes Human genes 0.000 description 10
- 108090000623 proteins and genes Proteins 0.000 description 10
- 208000024891 symptom Diseases 0.000 description 8
- 229940088598 enzyme Drugs 0.000 description 7
- 235000008476 powdered milk Nutrition 0.000 description 7
- 239000002131 composite material Substances 0.000 description 5
- 206010012735 Diarrhoea Diseases 0.000 description 4
- 108060003951 Immunoglobulin Proteins 0.000 description 4
- 208000009793 Milk Hypersensitivity Diseases 0.000 description 4
- 201000010859 Milk allergy Diseases 0.000 description 4
- 235000020616 amino acid formula Nutrition 0.000 description 4
- 238000003745 diagnosis Methods 0.000 description 4
- 230000002496 gastric effect Effects 0.000 description 4
- 102000018358 immunoglobulin Human genes 0.000 description 4
- 230000008569 process Effects 0.000 description 4
- 230000000172 allergic effect Effects 0.000 description 3
- 150000001413 amino acids Chemical class 0.000 description 3
- 208000010668 atopic eczema Diseases 0.000 description 3
- 238000005516 engineering process Methods 0.000 description 3
- 230000006870 function Effects 0.000 description 3
- 235000016709 nutrition Nutrition 0.000 description 3
- 230000017854 proteolysis Effects 0.000 description 3
- 238000012360 testing method Methods 0.000 description 3
- PEDCQBHIVMGVHV-UHFFFAOYSA-N Glycerine Chemical group OCC(O)CO PEDCQBHIVMGVHV-UHFFFAOYSA-N 0.000 description 2
- GUBGYTABKSRVRQ-QKKXKWKRSA-N Lactose Natural products OC[C@H]1O[C@@H](O[C@H]2[C@H](O)[C@@H](O)C(O)O[C@@H]2CO)[C@H](O)[C@@H](O)[C@H]1O GUBGYTABKSRVRQ-QKKXKWKRSA-N 0.000 description 2
- 201000010538 Lactose Intolerance Diseases 0.000 description 2
- 101710094902 Legumin Proteins 0.000 description 2
- 244000046052 Phaseolus vulgaris Species 0.000 description 2
- 235000010627 Phaseolus vulgaris Nutrition 0.000 description 2
- 230000009286 beneficial effect Effects 0.000 description 2
- 230000008859 change Effects 0.000 description 2
- 210000003022 colostrum Anatomy 0.000 description 2
- 235000021277 colostrum Nutrition 0.000 description 2
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 2
- NEKNNCABDXGBEN-UHFFFAOYSA-L disodium;4-(4-chloro-2-methylphenoxy)butanoate;4-(2,4-dichlorophenoxy)butanoate Chemical compound [Na+].[Na+].CC1=CC(Cl)=CC=C1OCCCC([O-])=O.[O-]C(=O)CCCOC1=CC=C(Cl)C=C1Cl NEKNNCABDXGBEN-UHFFFAOYSA-L 0.000 description 2
- 208000037902 enteropathy Diseases 0.000 description 2
- 238000011156 evaluation Methods 0.000 description 2
- 235000019197 fats Nutrition 0.000 description 2
- 235000013305 food Nutrition 0.000 description 2
- 208000028774 intestinal disease Diseases 0.000 description 2
- 230000000968 intestinal effect Effects 0.000 description 2
- 239000008101 lactose Substances 0.000 description 2
- 230000004048 modification Effects 0.000 description 2
- 238000012986 modification Methods 0.000 description 2
- 230000000474 nursing effect Effects 0.000 description 2
- 230000035764 nutrition Effects 0.000 description 2
- ZCYVEMRRCGMTRW-UHFFFAOYSA-N 7553-56-2 Chemical group [I] ZCYVEMRRCGMTRW-UHFFFAOYSA-N 0.000 description 1
- GUBGYTABKSRVRQ-XLOQQCSPSA-N Alpha-Lactose Chemical compound O[C@@H]1[C@@H](O)[C@@H](O)[C@@H](CO)O[C@H]1O[C@@H]1[C@@H](CO)O[C@H](O)[C@H](O)[C@H]1O GUBGYTABKSRVRQ-XLOQQCSPSA-N 0.000 description 1
- 206010002198 Anaphylactic reaction Diseases 0.000 description 1
- 241000283690 Bos taurus Species 0.000 description 1
- 206010051228 Chylothorax Diseases 0.000 description 1
- KRKNYBCHXYNGOX-UHFFFAOYSA-K Citrate Chemical compound [O-]C(=O)CC(O)(CC([O-])=O)C([O-])=O KRKNYBCHXYNGOX-UHFFFAOYSA-K 0.000 description 1
- 108010016626 Dipeptides Proteins 0.000 description 1
- WSFSSNUMVMOOMR-UHFFFAOYSA-N Formaldehyde Chemical compound O=C WSFSSNUMVMOOMR-UHFFFAOYSA-N 0.000 description 1
- 206010053759 Growth retardation Diseases 0.000 description 1
- 208000034767 Hypoproteinaemia Diseases 0.000 description 1
- 244000078118 Ilex latifolia Species 0.000 description 1
- 235000008706 Ilex latifolia Nutrition 0.000 description 1
- 206010025476 Malabsorption Diseases 0.000 description 1
- 208000004155 Malabsorption Syndromes Diseases 0.000 description 1
- 102000019280 Pancreatic lipases Human genes 0.000 description 1
- 108050006759 Pancreatic lipases Proteins 0.000 description 1
- 229930006000 Sucrose Natural products 0.000 description 1
- CZMRCDWAGMRECN-UGDNZRGBSA-N Sucrose Chemical compound O[C@H]1[C@H](O)[C@@H](CO)O[C@@]1(CO)O[C@@H]1[C@H](O)[C@@H](O)[C@H](O)[C@@H](CO)O1 CZMRCDWAGMRECN-UGDNZRGBSA-N 0.000 description 1
- 206010047700 Vomiting Diseases 0.000 description 1
- 208000003455 anaphylaxis Diseases 0.000 description 1
- 235000019611 bitter taste sensations Nutrition 0.000 description 1
- 230000037396 body weight Effects 0.000 description 1
- 210000000481 breast Anatomy 0.000 description 1
- 238000006243 chemical reaction Methods 0.000 description 1
- 229940099352 cholate Drugs 0.000 description 1
- BHQCQFFYRZLCQQ-OELDTZBJSA-N cholic acid Chemical compound C([C@H]1C[C@H]2O)[C@H](O)CC[C@]1(C)[C@@H]1[C@@H]2[C@@H]2CC[C@H]([C@@H](CCC(O)=O)C)[C@@]2(C)[C@@H](O)C1 BHQCQFFYRZLCQQ-OELDTZBJSA-N 0.000 description 1
- 208000019902 chronic diarrheal disease Diseases 0.000 description 1
- 210000001268 chyle Anatomy 0.000 description 1
- 208000002274 chylous ascites Diseases 0.000 description 1
- 230000007423 decrease Effects 0.000 description 1
- 235000021245 dietary protein Nutrition 0.000 description 1
- 201000010099 disease Diseases 0.000 description 1
- 230000004064 dysfunction Effects 0.000 description 1
- 150000004665 fatty acids Chemical class 0.000 description 1
- 238000005187 foaming Methods 0.000 description 1
- 239000013568 food allergen Substances 0.000 description 1
- 229960004279 formaldehyde Drugs 0.000 description 1
- 235000019256 formaldehyde Nutrition 0.000 description 1
- 238000009472 formulation Methods 0.000 description 1
- 230000007661 gastrointestinal function Effects 0.000 description 1
- 235000011187 glycerol Nutrition 0.000 description 1
- PCHJSUWPFVWCPO-UHFFFAOYSA-N gold Chemical compound [Au] PCHJSUWPFVWCPO-UHFFFAOYSA-N 0.000 description 1
- 229910052737 gold Inorganic materials 0.000 description 1
- 239000010931 gold Substances 0.000 description 1
- 231100000001 growth retardation Toxicity 0.000 description 1
- 235000020256 human milk Nutrition 0.000 description 1
- 210000004251 human milk Anatomy 0.000 description 1
- 235000020207 hydrolysed-protein milk formula Nutrition 0.000 description 1
- 230000002209 hydrophobic effect Effects 0.000 description 1
- 125000001165 hydrophobic group Chemical group 0.000 description 1
- 230000036039 immunity Effects 0.000 description 1
- 230000000937 inactivator Effects 0.000 description 1
- 229910052740 iodine Inorganic materials 0.000 description 1
- 239000011630 iodine Substances 0.000 description 1
- 238000002372 labelling Methods 0.000 description 1
- 230000007774 longterm Effects 0.000 description 1
- QJGQUHMNIGDVPM-UHFFFAOYSA-N nitrogen group Chemical group [N] QJGQUHMNIGDVPM-UHFFFAOYSA-N 0.000 description 1
- 230000000050 nutritive effect Effects 0.000 description 1
- 229940116369 pancreatic lipase Drugs 0.000 description 1
- 229920001184 polypeptide Polymers 0.000 description 1
- 235000013406 prebiotics Nutrition 0.000 description 1
- 230000002265 prevention Effects 0.000 description 1
- 230000009862 primary prevention Effects 0.000 description 1
- 102000004196 processed proteins & peptides Human genes 0.000 description 1
- 239000000047 product Substances 0.000 description 1
- 235000004252 protein component Nutrition 0.000 description 1
- 230000003946 protein process Effects 0.000 description 1
- 238000011084 recovery Methods 0.000 description 1
- 230000009467 reduction Effects 0.000 description 1
- 230000001235 sensitizing effect Effects 0.000 description 1
- 238000007619 statistical method Methods 0.000 description 1
- 239000005720 sucrose Substances 0.000 description 1
- 239000006228 supernatant Substances 0.000 description 1
- 210000001779 taste bud Anatomy 0.000 description 1
- 238000010998 test method Methods 0.000 description 1
- 238000004448 titration Methods 0.000 description 1
- 150000003626 triacylglycerols Chemical class 0.000 description 1
- 230000008673 vomiting Effects 0.000 description 1
- 235000019786 weight gain Nutrition 0.000 description 1
Landscapes
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
Abstract
The invention provides an infant formula milk powder resisting protein allergy and a preparation method thereof. The formula powder contains a whey protein hydrolysate, and the whey protein hydrolysate is prepared by the following method: dissolving per 5.0 g of whey protein powder in 95ml of distilled water, keeping the solution in a water bath at 85 DEG C for 20 min, adjusting the pH value to 7.0, adding trypsin (with activity of 25000U / g), keep the hydrolysis temperature at 40 DEG C, hydrolyzing for 4 h, heating the hydrolysate in a water bath of 85 DEG C for 10 min for enzyme inactivation, centrifuging to remove the precipitate, regulating the pH value to 8.5, adding aminopeptidase (with activity of 10000U / g), and hydrolyzing at 50 DEG C for 6 h. the whey protein hydrolysate used in the formula powder is whey protein depth hydrolysate with hydrolysis degree reaching 48-55%; and the whey protein peptide obtained from hydrolysis is easy for digestion and absorption, and has non allergenic property; and the bitter taste after depth hydrolysis of the whey protein is eliminated, and the taste is easy to accept by infants.
Description
Technical field
The present invention relates to a kind of infant formula, especially a kind of infant formula of anti-albumen allergy.
Background technology
Milk protein is first part of food proteins of formula milk feeding infant picked-up normally, is also the food allergen of the most often being determined.The baby of milk protein irritated (cmpa) there will be the symptoms such as vomiting, chronic diarrhea, malabsorption and growth retardation conventionally.Milk protein allergy refers to the bad reaction to milk protein of a kind of IgE or non-IgE mediation, and within 2 years old, following baby's incidence is about 2%.If cmpa infant can not get correct diagnosis and treatment, the cmpa infant month more than 1/2 will develop into many food hypersenstivities, have a strong impact on the quality of life of infant and family thereof.Up to now, the absorption of strictly avoiding milk protein is the unique effective method for the treatment of cmpa.Therefore for infant and the early stage selecting properly muting sensitive of children formula, substitute original formulation, improve and promote the nutrition of cmpa infant and grow to seem particularly important.
Present stage, the treatment of milk protein allergy is different according to irritated situation, has beans based formulas milk, depth hydrolysis's formula milk and three kinds of formulas of amino acid formula milk available.Bovine colostrum infant formula patent CN201010242738.0 has emphasized that the immunoglobulin (Ig) of colostrum own improves infant immunity effect, and has considered FOS and GOS gold combination performance prebiotic function, can not change the allergic phenomena of babymilk albumen; Breast base lactose free infant formula powder has solved diarrhoea and diarrhoea recovery problem that baby's lactose intolerance causes, but there is no to solve baby's albumen allergic problem at all.Therefore, albumen allergic problem is the subject matter of this type of children's allergy.Because the irritated infant of part milk protein simultaneously can be irritated to legumin, and legumin is low compared with the bioavilability of milk protein, long-term use may cause growth of weight not enough, and European paediatrics allergy and clinical immunology Hui Ji U.S. pediatric nutrition can not recommend beans based formulas to be applied to prevention and the treatment of the irritated infant of milk protein.The case that is in a bad way or can not makes a definite diagnosis, first-selected depth hydrolysis's formula milk or the treatment of amino acid formula milk.Most infants that suffer from milk protein allergy can tolerate depth hydrolysis's formula powder, if still have allergy sufferers can only select to using amino acid as the formula of nitrogenous source to depth hydrolysis's formula, account for make a definite diagnosis 10%, show as serious enteropathy or multiple food hypersenstivity more.Therefore amino acid formula is as serious systemic anaphylaxis, the serious concurrent Hypoproteinemia of enteropathy or poor growth baby's first-selection formula.But pure amino acid formula powder is expensive, and mouthfeel is poor, and has avoided anaphylactogen completely, can not progressively tolerate, therefore can not be as primary prevention.Depth hydrolysis's protein prescription powder, by special process technologies such as heating, hydrolysis, significantly reduced the antigenicity of protein component, and nutritive value is similar to ordinary powdered milk, thereby the most conventional.
Thereby the initial object of application protein hydrolysate formula is to reach the object that reduces milk protein allergy risk by the allergenicity reducing or eliminates milk protein.Protein through hydrolysis supervisor treated water solution protein prescription consists of small peptide or amino acid, in theory compared with intact proteins absorption more easy to digest.
Lactalbumin its antigenicity after being hydrolyzed significantly reduces, and partial function characteristic also improves simultaneously, as foaming characteristic, dissolubility and emulsibility and mouthfeel etc.But owing to making to be wrapped in the hydrophobic group that intramolecule is bitter taste in the meeting of hydrolyzed whey protein process, come out, the polypeptide that contains more hydrophobic grouping contacts with people's taste bud and just can make people produce bitter taste sensation, thereby limit it, in product, applies.For baby, molecular weight, lower than dipeptides, the tripeptides of 1000Da, is beneficial to and digests and assimilates most, and still, along with the increase of hydrolysis degree, bitter taste increases gradually.
Therefore, the lactalbumin hydrolysate of the high debitterize of exploitation degree of hydrolysis is also applied to formula powder and makes it have the irritated effect of effective anti-albumen, will have very important social value.
Summary of the invention
Technical problem to be solved by this invention is to provide a kind of lactalbumin depth hydrolysis thing of debitterize, and is applied in a kind of infant formula of anti-albumen allergy.
Another technical problem to be solved by this invention is to provide the preparation method of the infant formula of above-mentioned anti-albumen allergy.
For solving the problems of the technologies described above, technical scheme of the present invention is:
A kind of infant formula of anti-albumen allergy, contain lactalbumin hydrolysate, described lactalbumin hydrolysate is prepared by following method: every 5.0g concentrated whey protein powder is dissolved in 95ml distilled water, in 85 ℃ of water-baths, keep after 20min, regulating pH is 7.0, add trypsase (vigor 25000U/g), keep 40 ℃ of hydrolysis temperatures, after hydrolysis 4h, 85 ℃ of heating water bath 10min of hydrolyzate enzyme that goes out, the centrifugal precipitation of going, regulate pH8.5, add aminopeptidase (vigor 10000U/g), 50 ℃ of hydrolysis temperatures, continue hydrolysis 6h.
Preferably, the infant formula of above-mentioned anti-albumen allergy, by solid glucose syrup, lactalbumin hydrolysate, mixed vegetable oil, medium chain triglyceride, mineral matter, B B-complex, long-chain polyunsaturated fatty acid, emulsifying agent, Choline Chloride, taurine, nucleotides and VBT form, by its parts by weight solid glucose syrup 30-50 part, lactalbumin hydrolysate 25-40 part, mixed vegetable oil 7-13 part, medium chain triglyceride 12-17 part, mineral matter 3-5 part, B B-complex 0.2-0.7 part, long-chain polyunsaturated fatty acid 0.1-0.3 part, emulsifying agent 0.05-0.09 part, Choline Chloride 0.03-0.07 part, taurine 0.02-0.05 part, nucleotides 0.02-0.04 part, VBT 0.005-0.01 part.
Preferably; the infant formula of above-mentioned anti-albumen allergy, by its 40 parts, parts by weight solid glucose syrup, 30 parts of lactalbumin hydrolysates, 10 parts of mixed vegetable oils, 15 parts of medium chain triglycerides, 4.115 parts, mineral matter, 0.5 part of B B-complex, 0.2 part of long-chain polyunsaturated fatty acid, 0.07 part of emulsifying agent, 0.05 part of Choline Chloride, 0.03 part of taurine, 0.027 part, nucleotides, 0.008 part of VBT.
Preferably, the infant formula of above-mentioned anti-albumen allergy, described mixed vegetable oil is one or more the mixing of soybean oil, sunflower oil, corn oil, palm oil, rapeseed oil; B B-complex is vitamin A, vitamin D, vitamin E, vitamin K
1, Cobastab
1, Cobastab
2, Cobastab
6, Cobastab
12, several or whole mixing in nicotinic acid, folic acid, choline, biotin; Mineral matter is several or whole mixing in calcium, phosphorus, potassium, sodium, chlorine, iron, zinc, copper, manganese, molybdenum, selenium, iodine, chromium; Long-chain polyunsaturated fatty acid is arachidonic acid (ARA) and/or DHA (DHA); Emulsifying agent is soybean lecithin or list, diglycerol fatty acid lemon acid ester; Nucleotides is one or more the mixing in 5 ' monophosphate cytidine, 5 ' uridine monophosphate disodium, 5 ' AMP, 5 ' uridine monophosphate disodium.
A preparation method for the infant formula of anti-albumen allergy, concrete preparation process is as follows:
(1) mixing of materials
Major ingredient: by formula measure solid glucose syrup, lactalbumin hydrolysate in major ingredient cylinder with 45-55 ℃ of purified water stirring and dissolving;
Small powder: by formula measure mineral matter, Choline Chloride, taurine, nucleotides, VBT respectively in special-purpose small powder cylinder with 45-55 ℃ of pure water stirring and dissolving;
Oil plant: measure mixed vegetable oil, medium chain triglyceride, long-chain polyunsaturated fatty acid by formula and add emulsifiers dissolve in carburetion cylinder;
(2) pasteurize
After being mixed with small powder, major ingredient at 80-100 ℃ after sterilization 5-10min, is cooled to immediately 40-45 ℃ in pasteurization machine;
(3) homogeneous
The raw material that is preheated to 60-70 ℃ is mixed with oil plant, is homogeneous under 10-20MPa condition at homogenizer pressure; Cool to 10 ℃ of following keeping in;
(4) Vacuum Concentration
By formula ratio, add purified water to dissolve B B-complex, add in the material after homogeneous, mixture is warming up to concentration and evaporation under 60-70 ℃ of condition;
(5) spraying is dry
After concentrating, material is sprayed and is dried, and drying condition is EAT 150-170 ℃, and logistics flow velocity is 1.20-1.30L/h, obtains.
Preferably, the preparation method of the infant formula of above-mentioned anti-albumen allergy, in described step (1), the preparation method of lactalbumin hydrolysate is: every 5.0g concentrated whey protein powder is dissolved in 95ml distilled water, in 85 ℃ of water-baths, keep after 20min, regulating pH is 7.0, add trypsase (vigor 25000U/g), keep 40 ℃ of hydrolysis temperatures, after hydrolysis 4h, 85 ℃ of heating water bath 10min of hydrolyzate enzyme that goes out, the centrifugal precipitation of going, regulate pH8.5, add aminopeptidase (vigor 10000U/g), 50 ℃ of hydrolysis temperatures, continue hydrolysis 6h.
The invention has the beneficial effects as follows:
The infant formula of above-mentioned anti-albumen allergy, lactalbumin hydrolysate used is lactalbumin depth hydrolysis thing, in specific proportioning situation, lactalbumin to be carried out to composite hydrolysis by trypsase and aminopeptidase, make its degree of hydrolysis reach 48-55%, nutritional labeling is without loss, the absorption easy to digest of hydrolysis gained whey protein peptide, without sensitizing property, has been eliminated the bitter taste after lactalbumin depth hydrolysis simultaneously, and taste is easy to infant and accepts;
And by the infant formula of specific prescription, preferably solid glucose syrup, not containing lactose and sucrose, applicable to lactose intolerance baby, and can promote baby intestinal energy to take in and body weight gain; During fat forms with medium chain triglyceride (medium chain triglyceride, MCT) substitute long-chain triglyceride (long-chain triglycerides, LCT), even the in the situation that of pancreatic lipase and the reduction of cholate level, also can absorb fast and effectively, do not produce chyle, be applicable to fat digestion, absorption and the dysbolism baby of (comprising chylothorax, chyloperitoneum), this infant formula is particularly applicable to the baby of intestinal dysfunction, especially has the baby of disturbance of absorptive function.
Accompanying drawing explanation
Fig. 1 is the graph of a relation (trypsase is hydrolyzed separately, aminopeptidase is hydrolyzed separately and the percent hydrolysis of trypsase-aminopeptidase composite hydrolysis and the comparison of hydrolysis time) of different hydrolyzate percent hydrolysis and hydrolysis time;
Fig. 2 is graph of a relation between different hydrolyzate bitterness value and hydrolysis time (trypsase is hydrolyzed separately, aminopeptidase is hydrolyzed separately and the bitterness value of trypsase-aminopeptidase composite hydrolysis and the comparison of hydrolysis time).
The specific embodiment
Below in conjunction with specific embodiment, technical scheme of the present invention is further described.
Embodiment 1
A kind of infant formula of anti-albumen allergy, by solid glucose syrup, lactalbumin hydrolysate, mixed vegetable oil, medium chain triglyceride, mineral matter, B B-complex, long-chain polyunsaturated fatty acid, emulsifying agent, Choline Chloride, taurine, nucleotides and VBT form, wherein, solid glucose syrup 40kg, lactalbumin hydrolysate 30kg, mixed vegetable oil 10kg, medium chain triglyceride 15kg, mineral matter 4.115kg, B B-complex 0.5kg, long-chain polyunsaturated fatty acid 0.2kg, emulsifying agent 0.07kg, Choline Chloride 0.05kg, taurine 0.03kg, nucleotides 0.027kg, VBT 0.008kg, described mixed vegetable oil is soybean oil and the palm oil oil for mixing that 1:1 forms by volume, described B B-complex is for counting by weight 466 parts of vitamin As, 7 parts of vitamin Ds, 8 parts of vitamin Es, vitamin K
138 parts, Cobastab
1372 parts, Cobastab
2847 parts, Cobastab
6315 parts, Cobastab
122.1 parts, the mixture of 328 parts, nicotinic acid, 88 parts, folic acid, 125 parts, choline, 18 parts of compositions of biotin, described mineral matter is for counting by weight the mixture of 548 parts of calcium, 340 parts, phosphorus, 665 parts, potassium, 177 parts, sodium, 392 parts of chlorine, 7.1 parts of iron, 4.5 parts, zinc, 316 parts of copper, 17 parts, manganese, 17 parts, selenium, 96 parts of compositions of iodine, described long-chain polyunsaturated fatty acid is the mixture that arachidonic acid (ARA) and DHA (DHA) form by weight 1:1, described emulsifying agent is soybean lecithin, described nucleotides is 5 ' monophosphate cytidine.
The preparation method of the infant formula of above-mentioned anti-albumen allergy, concrete preparation process is as follows:
(1) mixing of materials
Major ingredient: by formula measure solid glucose syrup, lactalbumin hydrolysate in major ingredient cylinder with 45 ℃ of purified water stirring and dissolving;
Small powder: by formula measure mineral matter, Choline Chloride, taurine, nucleotides, VBT respectively in special-purpose small powder cylinder with 45 ℃ of pure water stirring and dissolving;
Oil plant: measure mixed vegetable oil, medium chain triglyceride, long-chain polyunsaturated fatty acid by formula and add emulsifiers dissolve in carburetion cylinder;
(2) pasteurize
After being mixed with small powder, major ingredient at 100 ℃ after sterilization 5min, is cooled to immediately 42 ℃ in pasteurization machine;
(3) homogeneous
The raw material that is preheated to 65 ℃ is mixed with oil plant, is homogeneous under 13MPa condition at homogenizer pressure; Cool to 10 ℃ of following keeping in;
(4) Vacuum Concentration
By formula ratio, add purified water to dissolve B B-complex, add in the material after homogeneous, mixture is warming up to concentration and evaporation under 65 ℃ of conditions;
(5) spraying is dry
After concentrating, material is sprayed and is dried, and drying condition is 152 ℃ of EATs, and logistics flow velocity is 1.23L/h, obtains.
Embodiment 2
A kind of infant formula of anti-albumen allergy, by solid glucose syrup, lactalbumin hydrolysate, mixed vegetable oil, medium chain triglyceride, mineral matter, B B-complex, long-chain polyunsaturated fatty acid, emulsifying agent, Choline Chloride, taurine, nucleotides and VBT form, wherein, solid glucose syrup 50kg, lactalbumin hydrolysate 25kg, mixed vegetable oil 7kg, medium chain triglyceride 17kg, mineral matter 5kg, B B-complex 0.2kg, long-chain polyunsaturated fatty acid 0.1kg, emulsifying agent 0.09kg, Choline Chloride 0.07kg, taurine 0.02kg, nucleotides 0.02kg, VBT 0.01kg, described mixed vegetable oil is soybean oil and the palm oil oil for mixing that 1:1 forms by volume, described B B-complex is for counting by weight 466 parts of vitamin As, 7 parts of vitamin Ds, 8 parts of vitamin Es, vitamin K
138 parts, Cobastab
1372 parts, Cobastab
2847 parts, Cobastab
6315 parts, Cobastab
122.1 parts, the mixture of 328 parts, nicotinic acid, 88 parts, folic acid, 125 parts, choline, 18 parts of compositions of biotin, described mineral matter is for counting by weight the mixture of 548 parts of calcium, 340 parts, phosphorus, 665 parts, potassium, 177 parts, sodium, 392 parts of chlorine, 7.1 parts of iron, 4.5 parts, zinc, 316 parts of copper, 17 parts, manganese, 17 parts, selenium, 96 parts of compositions of iodine, described long-chain polyunsaturated fatty acid is the mixture that arachidonic acid (ARA) and DHA (DHA) form by weight 1:1, described emulsifying agent is soybean lecithin, described nucleotides is 5 ' monophosphate cytidine.
The preparation method of the infant formula of above-mentioned anti-albumen allergy, concrete preparation process is as follows:
(1) mixing of materials
Major ingredient: by formula measure solid glucose syrup, lactalbumin hydrolysate in major ingredient cylinder with 48 ℃ of purified water stirring and dissolving;
Small powder: by formula measure mineral matter, Choline Chloride, taurine, nucleotides, VBT respectively in special-purpose small powder cylinder with 52 ℃ of pure water stirring and dissolving;
Oil plant: measure mixed vegetable oil, medium chain triglyceride, long-chain polyunsaturated fatty acid by formula and add emulsifiers dissolve in carburetion cylinder;
(2) pasteurize
After being mixed with small powder, major ingredient at 80 ℃ after sterilization 8min, is cooled to immediately 40 ℃ in pasteurization machine;
(3) homogeneous
The raw material that is preheated to 70 ℃ is mixed with oil plant, is homogeneous under 15MPa condition at homogenizer pressure; Cool to 10 ℃ of following keeping in;
(4) Vacuum Concentration
By formula ratio, add purified water to dissolve B B-complex, add in the material after homogeneous, mixture is warming up to concentration and evaporation under 60 ℃ of conditions;
(5) spraying is dry
After concentrating, material is sprayed and is dried, and drying condition is 160 ℃ of EATs, and logistics flow velocity is 1.25L/h, obtains.
Embodiment 3
A kind of infant formula of anti-albumen allergy, by solid glucose syrup, lactalbumin hydrolysate, mixed vegetable oil, medium chain triglyceride, mineral matter, B B-complex, long-chain polyunsaturated fatty acid, emulsifying agent, Choline Chloride, taurine, nucleotides and VBT form, wherein, solid glucose syrup 30kg, lactalbumin hydrolysate 40kg, mixed vegetable oil 13kg, medium chain triglyceride 12kg, mineral matter 3kg, B B-complex 0.7kg, long-chain polyunsaturated fatty acid 0.3kg, emulsifying agent 0.05kg, Choline Chloride 0.03kg, taurine 0.05kg, nucleotides 0.04kg, VBT 0.005kg, described mixed vegetable oil is soybean oil and the palm oil oil for mixing that 1:1 forms by volume, described B B-complex is for counting by weight 466 parts of vitamin As, 7 parts of vitamin Ds, 8 parts of vitamin Es, vitamin K
138 parts, Cobastab
1372 parts, Cobastab
2847 parts, Cobastab
6315 parts, Cobastab
122.1 parts, the mixture of 328 parts, nicotinic acid, 88 parts, folic acid, 125 parts, choline, 18 parts of compositions of biotin, described mineral matter is for counting by weight the mixture of 548 parts of calcium, 340 parts, phosphorus, 665 parts, potassium, 177 parts, sodium, 392 parts of chlorine, 7.1 parts of iron, 4.5 parts, zinc, 316 parts of copper, 17 parts, manganese, 17 parts, selenium, 96 parts of compositions of iodine, described long-chain polyunsaturated fatty acid is the mixture that arachidonic acid (ARA) and DHA (DHA) form by weight 1:1, described emulsifying agent is soybean lecithin, described nucleotides is 5 ' monophosphate cytidine.
The preparation method of the infant formula of above-mentioned anti-albumen allergy, concrete preparation process is as follows:
(1) mixing of materials
Major ingredient: by formula measure solid glucose syrup, lactalbumin hydrolysate in major ingredient cylinder with 50 ℃ of purified water stirring and dissolving;
Small powder: by formula measure mineral matter, Choline Chloride, taurine, nucleotides, VBT respectively in special-purpose small powder cylinder with 48 ℃ of pure water stirring and dissolving;
Oil plant: measure mixed vegetable oil, medium chain triglyceride, long-chain polyunsaturated fatty acid by formula and add emulsifiers dissolve in carburetion cylinder;
(2) pasteurize
After being mixed with small powder, major ingredient at 90 ℃ after sterilization 10min, is cooled to immediately 40 ℃ in pasteurization machine;
(3) homogeneous
The raw material that is preheated to 60 ℃ is mixed with oil plant, is homogeneous under 18MPa condition at homogenizer pressure; Cool to 10 ℃ of following keeping in;
(4) Vacuum Concentration
By formula ratio, add purified water to dissolve B B-complex, add in the material after homogeneous, mixture is warming up to concentration and evaporation under 70 ℃ of conditions;
(5) spraying is dry
After concentrating, material is sprayed and is dried, and drying condition is 165 ℃ of EATs, and logistics flow velocity is 1.28L/h, obtains.
Embodiment 4
A kind of infant formula of anti-albumen allergy, by solid glucose syrup, lactalbumin hydrolysate, mixed vegetable oil, medium chain triglyceride, mineral matter, B B-complex, long-chain polyunsaturated fatty acid, emulsifying agent, Choline Chloride, taurine, nucleotides and VBT form, wherein, solid glucose syrup 38kg, lactalbumin hydrolysate 28kg, mixed vegetable oil 11kg, medium chain triglyceride 16kg, mineral matter 4.2kg, B B-complex 0.48kg, long-chain polyunsaturated fatty acid 0.26kg, emulsifying agent 0.07kg, Choline Chloride 0.06kg, taurine 0.04kg, nucleotides 0.02kg, VBT 0.008kg.Described mixed vegetable oil is sunflower oil and the corn oil oil for mixing that 1:1 forms by volume; Described B B-complex is for counting by weight 49 parts of vitamin As, 56 parts of VD1s, 1 part of vitamin E2, vitamin K
165 parts, Cobastab
124 parts, Cobastab
251 parts, Cobastab
623 parts, Cobastab
12104 parts, the mixture of 17 parts, nicotinic acid, 76 parts, folic acid, 25 parts, choline, 17 parts of compositions of biotin; Described mineral matter is for counting by weight the mixture of 108 parts of calcium, 93 parts, phosphorus, 55 parts, potassium, 59 parts of iron, 46 parts, zinc, 35 parts of copper, 20 parts, selenium, 47 parts of compositions of iodine; Described long-chain polyunsaturated fatty acid is the mixture that arachidonic acid (ARA) and DHA (DHA) form by weight 1.5:1; Described emulsifying agent is glycerine fatty acid citrate; Described nucleotides is 5 ' AMP.
The preparation method of the infant formula of above-mentioned anti-albumen allergy, concrete preparation process is as follows:
(1) mixing of materials
Major ingredient: by formula measure solid glucose syrup, lactalbumin hydrolysate in major ingredient cylinder with 45 ℃ of purified water stirring and dissolving;
Small powder: by formula measure mineral matter, Choline Chloride, taurine, nucleotides, VBT respectively in special-purpose small powder cylinder with 45 ℃ of pure water stirring and dissolving;
Oil plant: measure mixed vegetable oil, medium chain triglyceride, long-chain polyunsaturated fatty acid by formula and add emulsifiers dissolve in carburetion cylinder;
(2) pasteurize
After being mixed with small powder, major ingredient at 95 ℃ after sterilization 10min, is cooled to immediately 45 ℃ in pasteurization machine;
(3) homogeneous
The raw material that is preheated to 65 ℃ is mixed with oil plant, is homogeneous under 20MPa condition at homogenizer pressure; Cool to 10 ℃ of following keeping in;
(4) Vacuum Concentration
By formula ratio, add purified water to dissolve B B-complex, add in the material after homogeneous, mixture is warming up to concentration and evaporation under 65 ℃ of conditions;
(5) spraying is dry
After concentrating, material is sprayed and is dried, and drying condition is 170 ℃ of EATs, and logistics flow velocity is 1.30L/h, obtains.
The described lactalbumin hydrolysate of one of embodiment 1-4 is prepared by following method: every 5.0g concentrated whey protein powder is dissolved in 95ml distilled water, in 85 ℃ of water-baths, keep after 20min, regulating pH is 7.0, add trypsase (vigor 25000U/g), keep 40 ℃ of hydrolysis temperatures, after hydrolysis 4h, 85 ℃ of heating water bath 10min of hydrolyzate enzyme that goes out, the centrifugal precipitation of going, regulates pH8.5, add aminopeptidase (vigor 10000U/g), 50 ℃ of hydrolysis temperatures, continue hydrolysis 6h, after being hydrolyzed, the rapid warming-in-water to 90 ℃ of hydrolyzate, maintains 15min inactivator.Hydrolyzate, in the centrifugal 20min of 4000r/min, is discarded to precipitation, the lactalbumin depth hydrolysis thing that supernatant is debitterize; Other components are commercially available prod, and each amounts of components is increased or reduced according to same ratio, and the parts by weight relation of each component of gained all belongs to protection scope of the present invention.
Test case 1
Trypsase is hydrolyzed separately, aminopeptidase is hydrolyzed separately and the comparison of percent hydrolysis, bitterness value and the hydrolysis time of trypsase-aminopeptidase composite hydrolysis
Method of testing:
Trypsase is hydrolyzed separately: every 5.0g concentrated whey protein powder is dissolved in 95ml distilled water, in 85 ℃ of water-baths, keeps after 20min, regulating pH is 7.0, adds trypsase (vigor 25000U/g), keeps 40 ℃ of hydrolysis temperatures, hydrolysis 10h.In hydrolytic process, every 2h, get a certain amount of hydrolyzate, for measuring proteolysis rate and bitter taste score value;
Aminopeptidase is hydrolyzed separately: every 5.0g concentrated whey protein powder is dissolved in 95ml distilled water, in 85 ℃ of water-baths, keeps after 20min, regulate pH8.5, add aminopeptidase (vigor 10000U/g), 50 ℃ of hydrolysis temperatures, hydrolysis 10h.In hydrolytic process, every 2h, get a certain amount of hydrolyzate, for measuring proteolysis rate and bitter taste score value;
Complex enzyme for hydrolyzing: every 5.0g concentrated whey protein powder is dissolved in 95ml distilled water, in 85 ℃ of water-baths, keep after 20min, regulating pH is 7.0, adds trypsase (vigor 25000U/g), keep 40 ℃ of hydrolysis temperatures, after hydrolysis 4h, 85 ℃ of heating water bath 10min of hydrolyzate enzyme that goes out, the centrifugal precipitation of going, regulate pH8.5, add aminopeptidase (vigor 10000U/g), 50 ℃ of hydrolysis temperatures, continue hydrolysis 6h.In hydrolytic process, every 2h, get a certain amount of hydrolyzate, for measuring proteolysis rate and bitter taste score value.
The mensuration of percent hydrolysis: adopt formol titration.
Bitter taste estimate: take 2g Ilex Latifolia Thunb, add 500ml distilled water and boil 30min, filter, be settled to 500ml.Dilute respectively 20,40,60,80,100 times, with 10 powder systems, assess, bitter taste score value is evaluation group (10 people's) average.Standards of grading: without bitter taste: 2; Micro-hardship: 4; More bitter: 6; Bitter: 8; Very bitter: 10.
As shown in Figure 1 and Figure 2, same hydrolysis is under the time, single use trypsase and the hydrolysis degree no significant difference that uses complex enzyme for hydrolyzing, and use separately aminopeptidase percent hydrolysis lower; The hydrolyzate bitter taste score value of complex enzyme hydrolysis is starkly lower than the hydrolyzate of single use trypsin hydrolysis; Consider the factors such as hydrolysis time, hydrolysis degree and hydrolyzate bitter taste, optimize hydrolysising condition, trypsase-aminopeptidase composite hydrolysis lactalbumin of employing special ratios can obtain low bitter taste depth hydrolysis's hydrolysate.
Test case 2
The observation of curative effect of depth hydrolysis's protein prescription powder to milk allergy infant gastrointestinal function
Test crowd: select to intend being diagnosed as milk allergy infant 30 examples.The diagnostic criteria that all meets diarrhea disease of inpatient children diagnoses and treatment principle in 2009 and the hypersensitive diagnosis of infant's milk protein and treatment guide.This is organized in 30 routine infants, male 16 examples, female's 14 examples; Age 2-6 month, average (4.2 ± 1.2) individual month; Course of disease 3d-2 month.The performance of infant gastrointestinal symptom is in Table 1.
Methods for the treatment of: the ordinary powdered milk of stopping using, to use the infant formula of anti-albumen allergy described in the embodiment of the present invention 1 instead and feed, mixed feeding infant adopts and stops breast milk and breast-feeds, simple depth hydrolysis's protein prescription powder, the nursing time is 2 weeks.After 2 weeks, can try to feed ordinary powdered milk, initial amount is that 1/4 ordinary powdered milk mixes 3/4 depth hydrolysis's protein prescription powder, observes stool proterties 2-3d; Stool normally increases by 1/4 then again, and 1/2 ordinary powdered milk mixes 1/2 depth hydrolysis's protein prescription powder, observes stool proterties 2-3d; The infant formula that stool proterties is extremely changeed back anti-albumen allergy described in embodiment 1 is fed; As follows analogize each increase by 1/4 ordinary powdered milk, until excessively to 100% ordinary powdered milk.Medical worker carries out Effect of follow-up visit by telephone gastrointestinal symptom for 1 week, 2 weeks and 4 weeks in nursing.And record and compare infant treatment before and the treatment 4 weeks variation of the indexs such as periphery immunoglobulin (Ig)s afterwards.Statistics is in Table 2 and table 3.
Evaluation index: observe and record infant result for the treatment of.Treatment results is effective: after infant treatment, symptom significantly took a turn for the better in one week; Effective: after infant treatment, in two weeks, symptom takes a turn for the better; Invalid: after infant treatment in surrounding symptom without significant change.
Statistical method: each variable represents with x ± s.Adopt t check, P<0.05 has statistical significance by being considered to checked difference.
Conclusion: the formula that adopts the lactalbumin hydrolysate that contains depth hydrolysis, and utilize the particular combination of solid glucose syrup, medium chain triglyceride etc., high molecular weight protein is hydrolyzed to little peptide and amino acid, modification structure and the steric configuration of high molecular weight protein have effectively been reduced, eliminate the sensibiligen in milk, effectively alleviated infant gastrointestinal symptom; After infant treatment, periphery Immunoglobulin IgE level is treated front obvious decline, significant difference (P<0.01).Further confirmed that Immunoglobulin IgE plays an important role in babymilk allergy and the clinical effective property of this formula powder.
The routine gastrointestinal symptom performance of table 1 milk allergy infant 30 (example, %)
Table 2 milk allergy infant 30 routine results for the treatment of
Before and after the treatment of table 3 infant, periphery amynologic index changes
Above-mentioned detailed description of infant formula of this kind of anti-albumen allergy and preparation method thereof being carried out with reference to embodiment; illustrative rather than determinate; can list several embodiment according to institute's limited range; therefore in the variation and the modification that do not depart under general plotting of the present invention, within should belonging to protection scope of the present invention.
Claims (6)
1. the infant formula of an anti-albumen allergy, contain lactalbumin hydrolysate, it is characterized in that: described lactalbumin hydrolysate is prepared by following method: every 5.0g concentrated whey protein powder is dissolved in 95ml distilled water, in 85 ℃ of water-baths, keep after 20min, regulating pH is 7.0, add trypsase, keep 40 ℃ of hydrolysis temperatures, after hydrolysis 4h, 85 ℃ of heating water bath 10min of hydrolyzate enzyme that goes out, the centrifugal precipitation of going, regulate pH8.5, add aminopeptidase, 50 ℃ of hydrolysis temperatures, continue hydrolysis 6h.
2. the infant formula of anti-albumen allergy according to claim 1, it is characterized in that: by solid glucose syrup, lactalbumin hydrolysate described in claim 1, mixed vegetable oil, medium chain triglyceride, mineral matter, B B-complex, long-chain polyunsaturated fatty acid, emulsifying agent, Choline Chloride, taurine, nucleotides and VBT form, by its parts by weight solid glucose syrup 30-50 part, lactalbumin hydrolysate 25-40 part, mixed vegetable oil 7-13 part, medium chain triglyceride 12-17 part, mineral matter 3-5 part, B B-complex 0.2-0.7 part, long-chain polyunsaturated fatty acid 0.1-0.3 part, emulsifying agent 0.05-0.09 part, Choline Chloride 0.03-0.07 part, taurine 0.02-0.05 part, nucleotides 0.02-0.04 part, VBT 0.005-0.01 part.
3. the infant formula of anti-albumen allergy according to claim 2, is characterized in that: by its 40 parts, parts by weight solid glucose syrup, 30 parts of lactalbumin hydrolysates, 10 parts of mixed vegetable oils, 15 parts of medium chain triglycerides, 4.115 parts, mineral matter, 0.5 part of B B-complex, 0.2 part of long-chain polyunsaturated fatty acid, 0.07 part of emulsifying agent, 0.05 part of Choline Chloride, 0.03 part of taurine, 0.027 part, nucleotides, 0.008 part of VBT.
4. according to the infant formula of the anti-albumen allergy described in claim 2 or 3, it is characterized in that: described mixed vegetable oil is one or more the mixing of soybean oil, sunflower oil, corn oil, palm oil, rapeseed oil; B B-complex is vitamin A, vitamin D, vitamin E, vitamin K
1, Cobastab
1, Cobastab
2, Cobastab
6, Cobastab
12, several or whole mixing in nicotinic acid, folic acid, choline, biotin; Mineral matter is several or whole mixing in calcium, phosphorus, potassium, sodium, chlorine, iron, zinc, copper, manganese, molybdenum, selenium, iodine, chromium; Long-chain polyunsaturated fatty acid is arachidonic acid and/or DHA; Emulsifying agent is soybean lecithin or list, diglycerol fatty acid lemon acid ester; Nucleotides is one or more the mixing in 5 ' monophosphate cytidine, 5 ' uridine monophosphate disodium, 5 ' AMP, 5 ' uridine monophosphate disodium.
5. the preparation method of the infant formula of anti-albumen allergy described in claim 2, is characterized in that: concrete preparation process is as follows:
(1) mixing of materials
Major ingredient: by formula measure solid glucose syrup, lactalbumin hydrolysate in major ingredient cylinder with 45-55 ℃ of purified water stirring and dissolving;
Small powder: by formula measure mineral matter, Choline Chloride, taurine, nucleotides, VBT respectively in special-purpose small powder cylinder with 45-55 ℃ of pure water stirring and dissolving;
Oil plant: measure mixed vegetable oil, medium chain triglyceride, long-chain polyunsaturated fatty acid by formula and add emulsifiers dissolve in carburetion cylinder;
(2) pasteurize
After being mixed with small powder, major ingredient at 80-100 ℃ after sterilization 5-10min, is cooled to immediately 40-45 ℃ in pasteurization machine;
(3) homogeneous
The raw material that is preheated to 60-70 ℃ is mixed with oil plant, is homogeneous under 10-20MPa condition at homogenizer pressure; Cool to 10 ℃ of following keeping in;
(4) Vacuum Concentration
By formula ratio, add purified water to dissolve B B-complex, add in the material after homogeneous, mixture is warming up to concentration and evaporation under 60-70 ℃ of condition;
(5) spraying is dry
After concentrating, material is sprayed and is dried, and drying condition is EAT 150-170 ℃, and logistics flow velocity is 1.20-1.30L/h, obtains.
6. the preparation method of the infant formula of anti-albumen allergy according to claim 5, it is characterized in that: in described step (1), the preparation method of lactalbumin hydrolysate is: every 5.0g concentrated whey protein powder is dissolved in 95ml distilled water, in 85 ℃ of water-baths, keep after 20min, regulating pH is 7.0, add trypsase, keep 40 ℃ of hydrolysis temperatures, after hydrolysis 4h, 85 ℃ of heating water bath 10min of hydrolyzate enzyme that goes out, the centrifugal precipitation of going, regulates pH8.5, adds aminopeptidase, 50 ℃ of hydrolysis temperatures, continue hydrolysis 6h.
Priority Applications (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN201410282958.4A CN104054828B (en) | 2014-06-23 | 2014-06-23 | Infant formula of a kind of anti-albumen allergy and preparation method thereof |
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN201410282958.4A CN104054828B (en) | 2014-06-23 | 2014-06-23 | Infant formula of a kind of anti-albumen allergy and preparation method thereof |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| CN104054828A true CN104054828A (en) | 2014-09-24 |
| CN104054828B CN104054828B (en) | 2016-05-25 |
Family
ID=51542987
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CN201410282958.4A Expired - Fee Related CN104054828B (en) | 2014-06-23 | 2014-06-23 | Infant formula of a kind of anti-albumen allergy and preparation method thereof |
Country Status (1)
| Country | Link |
|---|---|
| CN (1) | CN104054828B (en) |
Cited By (16)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN105476012A (en) * | 2015-12-24 | 2016-04-13 | 中健医用食品有限公司 | Formula food with special medical application and preparation method thereof |
| CN107041546A (en) * | 2016-02-05 | 2017-08-15 | 上海他普亚贸易有限公司 | A kind of amino acid formula powder and preparation method thereof |
| CN108142562A (en) * | 2018-03-06 | 2018-06-12 | 青岛金大洋乳业有限公司 | A kind of formula powder and preparation method of the oral immunological tolerance of induction moderately hydrolyzed |
| CN108354169A (en) * | 2018-01-19 | 2018-08-03 | 新干县顾品佳营养食品有限公司 | A kind of nutrient formulation for helping to improve lactoprotein allergy |
| CN108851090A (en) * | 2018-03-14 | 2018-11-23 | 山东梵和生物科技有限公司 | It is a kind of moderately to hydrolyze muting sensitive formula powder and preparation method thereof |
| CN108851083A (en) * | 2018-03-14 | 2018-11-23 | 山东梵和生物科技有限公司 | A kind of depth hydrolysis' muting sensitive formula powder and preparation method thereof |
| CN108968052A (en) * | 2018-03-06 | 2018-12-11 | 青岛金大洋乳业有限公司 | A kind of formula powder reducing icterus neonatorum |
| CN108968053A (en) * | 2018-03-06 | 2018-12-11 | 青岛金大洋乳业有限公司 | A kind of muting sensitive formula powder of depth hydrolysis and preparation method thereof |
| CN108991503A (en) * | 2018-07-11 | 2018-12-14 | 谢碧平 | A kind of baby's special formulation powder rich in microelement |
| CN108991534A (en) * | 2018-03-14 | 2018-12-14 | 山东梵和生物科技有限公司 | A kind of formula powder reducing icterus neonatorum |
| CN109619570A (en) * | 2018-12-06 | 2019-04-16 | 中恩（天津）医药科技有限公司 | A kind of infant formula and preparation method thereof of anti-protein allergies |
| CN110037115A (en) * | 2019-05-14 | 2019-07-23 | 宁波特壹食品有限公司 | A kind of partially hydrolysed protein formula powder and preparation method thereof |
| CN111194914A (en) * | 2020-03-11 | 2020-05-26 | 汕头市培芝食品有限公司 | Infant formula food and preparation method thereof |
| CN114007435A (en) * | 2019-06-13 | 2022-02-01 | N·V·努特里奇亚 | Method for manufacturing an infant formula product containing hydrolyzed protein |
| CN114007436A (en) * | 2019-06-13 | 2022-02-01 | N·V·努特里奇亚 | Process for the preparation of a substantially lactose-free infant formula |
| EP3402573B1 (en) | 2016-01-13 | 2023-03-01 | Wolfgang Priemer | Composition containing amino acids |
Citations (3)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US5039532A (en) * | 1987-12-23 | 1991-08-13 | Nestec S.A. | Preparation of a hypoallergenic whey protein hydrolyzate and food |
| CN1656904A (en) * | 2005-03-16 | 2005-08-24 | 石家庄三鹿集团股份有限公司 | Formulated milk powder for baby and its preparation method |
| CN103621685A (en) * | 2013-12-05 | 2014-03-12 | 刘保惠 | Special medical infant formula milk powder with yak milk and preparation method thereof |
-
2014
- 2014-06-23 CN CN201410282958.4A patent/CN104054828B/en not_active Expired - Fee Related
Patent Citations (3)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US5039532A (en) * | 1987-12-23 | 1991-08-13 | Nestec S.A. | Preparation of a hypoallergenic whey protein hydrolyzate and food |
| CN1656904A (en) * | 2005-03-16 | 2005-08-24 | 石家庄三鹿集团股份有限公司 | Formulated milk powder for baby and its preparation method |
| CN103621685A (en) * | 2013-12-05 | 2014-03-12 | 刘保惠 | Special medical infant formula milk powder with yak milk and preparation method thereof |
Cited By (16)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN105476012A (en) * | 2015-12-24 | 2016-04-13 | 中健医用食品有限公司 | Formula food with special medical application and preparation method thereof |
| EP3402573B1 (en) | 2016-01-13 | 2023-03-01 | Wolfgang Priemer | Composition containing amino acids |
| CN107041546A (en) * | 2016-02-05 | 2017-08-15 | 上海他普亚贸易有限公司 | A kind of amino acid formula powder and preparation method thereof |
| CN108354169A (en) * | 2018-01-19 | 2018-08-03 | 新干县顾品佳营养食品有限公司 | A kind of nutrient formulation for helping to improve lactoprotein allergy |
| CN108142562A (en) * | 2018-03-06 | 2018-06-12 | 青岛金大洋乳业有限公司 | A kind of formula powder and preparation method of the oral immunological tolerance of induction moderately hydrolyzed |
| CN108968052A (en) * | 2018-03-06 | 2018-12-11 | 青岛金大洋乳业有限公司 | A kind of formula powder reducing icterus neonatorum |
| CN108968053A (en) * | 2018-03-06 | 2018-12-11 | 青岛金大洋乳业有限公司 | A kind of muting sensitive formula powder of depth hydrolysis and preparation method thereof |
| CN108851090A (en) * | 2018-03-14 | 2018-11-23 | 山东梵和生物科技有限公司 | It is a kind of moderately to hydrolyze muting sensitive formula powder and preparation method thereof |
| CN108851083A (en) * | 2018-03-14 | 2018-11-23 | 山东梵和生物科技有限公司 | A kind of depth hydrolysis' muting sensitive formula powder and preparation method thereof |
| CN108991534A (en) * | 2018-03-14 | 2018-12-14 | 山东梵和生物科技有限公司 | A kind of formula powder reducing icterus neonatorum |
| CN108991503A (en) * | 2018-07-11 | 2018-12-14 | 谢碧平 | A kind of baby's special formulation powder rich in microelement |
| CN109619570A (en) * | 2018-12-06 | 2019-04-16 | 中恩（天津）医药科技有限公司 | A kind of infant formula and preparation method thereof of anti-protein allergies |
| CN110037115A (en) * | 2019-05-14 | 2019-07-23 | 宁波特壹食品有限公司 | A kind of partially hydrolysed protein formula powder and preparation method thereof |
| CN114007435A (en) * | 2019-06-13 | 2022-02-01 | N·V·努特里奇亚 | Method for manufacturing an infant formula product containing hydrolyzed protein |
| CN114007436A (en) * | 2019-06-13 | 2022-02-01 | N·V·努特里奇亚 | Process for the preparation of a substantially lactose-free infant formula |
| CN111194914A (en) * | 2020-03-11 | 2020-05-26 | 汕头市培芝食品有限公司 | Infant formula food and preparation method thereof |
Also Published As
| Publication number | Publication date |
|---|---|
| CN104054828B (en) | 2016-05-25 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| CN104054828B (en) | Infant formula of a kind of anti-albumen allergy and preparation method thereof | |
| US8691213B2 (en) | Protein free formula | |
| CN102283290B (en) | Soybean-based infant formula powder and preparation method thereof | |
| CN103491973B (en) | For preventing the infant formula product of cardiovascular disease | |
| CN105360319A (en) | Child development formula milk powder and preparation method thereof | |
| CN107041546A (en) | A kind of amino acid formula powder and preparation method thereof | |
| CN103271241A (en) | Piglet forage ingredient and its preparation method and use | |
| AU2023226625A1 (en) | Heat sterilized high protein compositions with hydrolyzed protein from a continuous process with at least one endopeptidase | |
| CN110663958A (en) | Complementary food containing amino acid powder for infants and preparation method thereof | |
| WO2020122435A1 (en) | Rice milk employing rice protein and manufacturing method therefor | |
| CN114081110A (en) | Albumin enzymolysis beverage | |
| CN102458383A (en) | Opioid receptor stimulating compounds (thymoquinone, nigella sativa) and food allergy | |
| CN104619181B (en) | Method for preparing protein-containing composition for reducing digestive coagulation | |
| DE102004040452A1 (en) | peptide mixture | |
| CN108142562A (en) | A kind of formula powder and preparation method of the oral immunological tolerance of induction moderately hydrolyzed | |
| CN111194914A (en) | Infant formula food and preparation method thereof | |
| CN110999984A (en) | Hypoallergenic infant formula milk powder and preparation method thereof | |
| CN102533918B (en) | Method for preparing rapeseed active polypeptides | |
| WO2020252949A1 (en) | Protein composite for preventing and relieving sarcopenia in patients suffering from type 2 diabetes, and preparation method | |
| CN106306439A (en) | Milk cow forage and preparation method thereof | |
| CN113925170A (en) | Bean-based formula powder with anti-fatigue and immunity-improving functions and preparation method thereof | |
| CN105360926A (en) | Noodles rich in lysine and manufacturing method thereof | |
| AU710332B2 (en) | A nutritive composition containing milt | |
| CN111194916A (en) | Infant formula food added with enzymolysis grains and preparation method thereof | |
| CN112772929B (en) | Calcium supplement composition and preparation method thereof |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| C06 | Publication | ||
| PB01 | Publication | ||
| C10 | Entry into substantive examination | ||
| SE01 | Entry into force of request for substantive examination | ||
| CB03 | Change of inventor or designer information |
Inventor after: Wu Lebin Inventor after: Xu Cunmao Inventor after: Liu Guohong Inventor after: Liu Hanmin Inventor before: Wu Lebin Inventor before: Li Xuemei Inventor before: Liu Hanmin Inventor before: Hu Chenxu |
|
| COR | Change of bibliographic data | ||
| C14 | Grant of patent or utility model | ||
| GR01 | Patent grant | ||
| TR01 | Transfer of patent right | ||
| TR01 | Transfer of patent right |
Effective date of registration: 20170427 Address after: 300308 Tianjin Airport Economic Zone Binhai West Road No. 32 seven Patentee after: China (Tianjin) Medical Technology Co., Ltd. Address before: 300308 Tianjin Airport Economic Zone Binhai West Road No. 32 seven Patentee before: China (Tianjin) Nutrition Technology Co., Ltd. |
|
| CF01 | Termination of patent right due to non-payment of annual fee | ||
| CF01 | Termination of patent right due to non-payment of annual fee |
Granted publication date: 20160525 Termination date: 20170623 |